NHO Revive is proud to announce that it is the only clinical research site in Nebraska participating in KLK2-PASenger, a Phase 3 clinical trial evaluating Pasritamig (JNJ-78278343), an innovative bispecific T-cell redirecting therapy, in combination with docetaxel for patients with metastatic castration-resistant prostate cancer (mCRPC).
The study, sponsored by Johnson & Johnson, represents a significant advancement in prostate cancer treatment research. The investigational drug, Pasritamig is designed to harness the body's own immune system, specifically T-cells to target and attack cancer cells that express human kallikrein 2 (KLK2), a protein found on prostate cancer cells. This mechanism of action is distinct from traditional chemotherapy and hormone-based therapies, offering a potentially powerful new approach for patients whose disease has continued to progress despite existing treatments.
“Studies like the KLK2-PASenger prostate cancer trial allow us to bring innovative treatment options directly to patients here in Lincoln,” said Dr. Kailash Mosalpura, Medical Oncologist at Nebraska Hematology-Oncology. Being able to help patients with prostate cancer while also advancing the future of cancer care is incredibly meaningful for our team and our community.”
About the Trial
The KLK2-PASenger trial is a randomized, open-label study comparing Pasritamig plus docetaxel against docetaxel alone. The primary goal is to determine whether the combination extends the length of time patients live without their disease progressing on imaging scans. The study also evaluates overall survival, quality of life, and additional response measures.
Eligible participants must have histologically confirmed metastatic prostate adenocarcinoma that has progressed despite androgen deprivation therapy and at least one prior novel hormonal therapy. Patients must be 18 years or older with an ECOG performance status of 0 or 1.
